Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash & Current Investments: 2022-2024

Historic Cash & Current Investments for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $101.2 million.

  • Entrada Therapeutics' Cash & Current Investments rose 19.52% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.8 million, marking a year-over-year decrease of 16.16%. This contributed to the annual value of $101.2 million for FY2024, which is 49.72% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Cash & Current Investments of $101.2 million as of FY2024, which was up 49.72% from $67.6 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Cash & Current Investments registered a high of $101.2 million during FY2024, and its lowest value of $45.2 million during FY2022.
  • Its 3-year average for Cash & Current Investments is $71.3 million, with a median of $67.6 million in 2023.
  • Data for Entrada Therapeutics' Cash & Current Investments shows a peak YoY spiked of 49.72% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Cash & Current Investments stood at $45.2 million in 2022, then soared by 49.70% to $67.6 million in 2023, then surged by 49.72% to $101.2 million in 2024.